荆花胃康胶丸联合双歧杆菌治疗幽门螺杆菌感染的回顾性研究  

Retrospective study of Jinghua Weikang Capsule combined with bifidobacterium in treating Helicobacter pylori infection

作　　者：王秋明 周强[1] 胡晶[2] 丁洋[1] 张声生[1] WANG Qiuming;ZHOU Qiang;HU Jing;DING Yang;ZHANG Shengsheng(Department of Digestive Internal Medicine,Beijing Hospital of Traditional Chinese Medicine Attached to Capital Medical University,Beijing 100010,China;Centre for Evidence-Based Medicine,Beijing Institute of Traditional Chinese Medicine,Beijing 100010,China)

机构地区：[1]首都医科大学附属北京中医医院消化科,北京100010 [2]北京市中医研究所循证医学中心,北京100010

出　　处：《天津中医药》2022年第1期19-23,共5页Tianjin Journal of Traditional Chinese Medicine

基　　金：北京市中医管理局燕京流派创新传承“拳头”工程(20171101-脾胃)。

摘　　要：[目的]回顾性分析荆花胃康胶丸联合双歧杆菌治疗幽门螺杆菌(Hp)感染证属脾胃湿热证患者的临床疗效和安全性。[方法]选取首都医科大学附属北京中医医院门诊Hp感染证属脾胃湿热证病例115例,将其按照治疗方案分为3组,分别为标准四联组(35例)、荆花胃康胶丸+标准四联组(42例)、荆花胃康胶丸+双歧杆菌组(38例)。治疗2周后,停药4周以上,进行^(13)C或^(14)C呼气复查。观察对比3组病例中医单项症状频次与频率、中医证候疗效评价、Hp根除率及服药后不良反应的情况。[结果]Hp感染患者中医单项症状频率,依次为上腹胀、上腹痛、口臭。荆花胃康胶丸联合双歧杆菌组根除率(68.42%)与标准四联(80.00%)比较,差异无统计学意义(P>0.05)。荆花胃康胶丸联合标准四联组根除率(92.86%)高于荆花胃康胶丸联合双歧杆菌组(P<0.01),差异有统计学意义;与标准四联组相比差异无统计学意义(P>0.05)。荆花胃康胶丸联合双歧杆菌组中医证候疗效评价、不良反应优于其他两组,差异有统计学意义(P<0.05)。[结论]荆花胃康胶丸联合双歧杆菌能够在根除Hp的同时,兼顾改善患者临床症状,不良反应少。[Objective]To evaluate the therapeutic effect of Jinghua Weikang Capsule combined with bifidobacterium on patients with helicobacter pylori(Hp)infection and identified with the dampness-heat syndrome in the spleen and stomach.[Methods]This study was a retrospective research based on a total of 115 patients who were admitted to The Digestion Center of Beijing Hospital of Traditional Chinese Medicine Attached to Capital Medical University,with Hp infection and identified with the dampness-heat syndrome in the spleen and stomach.Via different treatment methods,the patients were divided into three groups:quadruple therapy group(35 cases),Jinghua Weikang Capsule combined with quadruple therapy group(42 cases)and Jinghua Weikang Capsule combined with bifidobacterium therapy group(38 cases).All cases were evaluated by 13C or 14C-urea breath test(UBT)after being treated for 14 days,with over 4 weeks long drug withdrawal.The single symptom frequency,therapeutic evaluation of clinical symptoms,eradication rate of helicobacter pylori and occurrence of adverse reactions were observed and assessed.[Results]For patients infected with Hp,the single symptom frequency was epigastric distention,epigastric pain and ozostomia in sequence.There was no significant statistical difference(P>0.05)in Hp eradication rate between the quadruple therapy group(80.00%)and the Jinghua Weikang Capsule combined with bifidobacterium therapy group(68.42%).Hp eradication rate of Jinghua Weikang Capsule combined with quadruple therapy group(92.86%)was higher than that of Jinghua Weikang Capsule combined with bifidobacterium therapy group,with the significant statistical difference(P<0.01);meanwhile,its Hp eradication rate was higher than that of quadruple therapy group,with no statistical difference(P>0.05).As for the therapeutic evaluation of clinical symptoms and adverse reactions,the Jinghua Weikang Capsule combined with bifidobacterium therapy group was obviously superior to the other two groups,with the significant statistical difference(P<0.05).

关 键 词：荆花胃康胶丸 双歧杆菌三联活菌 幽门螺杆菌 根除率 不良反应 

分 类 号：R573.3[医药卫生—消化系统]